
Key Presentations in Hodgkin and Non-Hodgkin Lymphomas from the 2022 ASH Annual Meeting with Dr Matthew Lunning
Oncology Today with Dr Neil Love
00:00
Indolent Lymphoma - Is Cellular Therapy a Good Thing?
If you can get into an early CR that's where the opportunity for durability is not only in large cell lymphoma but what it appears to be in indol lymphomas. The time point just may change a little bit and so I'm not panicking as much as I probably do in the large cell lymph cancer patient population. Where do we slot by specifics in a real after factory follicular lymphoma? We're looking at CD3, CD19 again and EPCO on your next mapYou know this is really bringing back you know CD3 engagers in non-Hodgens lymphoma or B Cell Lymphoma. It will move CAR T cell to the later lines
Transcript
Play full episode